Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$27,000.00
Characterizing Hypoxia as a Driver of Metastatic Soft Tissue Sarcoma
EF 2024-25
Résumé
Soft tissue sarcomas (STS) are rare cancers that arise in the body connective tissues. When these cancers are localized to one region, we can often effectively treat patients and prolong their survival. However, when these cancers spread to other organs, patient survival is greatly diminished, and conventional therapies are minimally effective. In the clinic, STS patients with metastatic disease are treated with doxorubicin, with or without ifosfamide, both of which are systemic chemotherapies. Yet, these patients generally do not survive past 15 months. This underscores the need to develop a more complete understanding of the biological drivers of STS metastasis to more effectively treat this phenomenon occurring in about half of all STS patients. Our lab and others have shown that exposure of STS cells to low oxygen levels (hypoxia) increases their ability to migrate and invade nearby tissues. However, whether exposure to hypoxia is sufficient to cause the metastatic colonization of STS cells in the lungs is unclear. In this study, we will use spatial biology techniques to visualize and understand how non-cancerous cells (e.g., immune cells) surrounding hypoxic regions in patient metastases can be leveraged for treatment. We will also assess how exposure of STS cells to hypoxia can affect their ability to resist the chemotherapies commonly used in the clinic to treat metastatic disease. Altogether, our study will help answer why nearly half of all STS metastasize and identify a potential vulnerability we can use to treat deadly metastatic disease.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
529638
Name
Symss Nathan D
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterizing Hypoxia as a Driver of Metastatic Soft Tissue Sarcoma
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Hypoxia; Metastasis; Soft Tissue Sarcoma; Spatial Biology; Treatment Resistance; Tumor Microenvironment; Undifferentiated Pleomorphic Sarcoma
Abstract
Soft tissue sarcomas (STS) are rare cancers that arise in the body connective tissues. When these cancers are localized to one region, we can often effectively treat patients and prolong their survival. However, when these cancers spread to other organs, patient survival is greatly diminished, and conventional therapies are minimally effective. In the clinic, STS patients with metastatic disease are treated with doxorubicin, with or without ifosfamide, both of which are systemic chemotherapies. Yet, these patients generally do not survive past 15 months. This underscores the need to develop a more complete understanding of the biological drivers of STS metastasis to more effectively treat this phenomenon occurring in about half of all STS patients. Our lab and others have shown that exposure of STS cells to low oxygen levels (hypoxia) increases their ability to migrate and invade nearby tissues. However, whether exposure to hypoxia is sufficient to cause the metastatic colonization of STS cells in the lungs is unclear. In this study, we will use spatial biology techniques to visualize and understand how non-cancerous cells (e.g., immune cells) surrounding hypoxic regions in patient metastases can be leveraged for treatment. We will also assess how exposure of STS cells to hypoxia can affect their ability to resist the chemotherapies commonly used in the clinic to treat metastatic disease. Altogether, our study will help answer why nearly half of all STS metastasize and identify a potential vulnerability we can use to treat deadly metastatic disease.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Symss, Nathan D
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~